This is a working overview of Fifteen residues, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
== Controversy == In 2020, Horsley was involved in a Twitter feud. In 2021, Horsley had a dispute with fellow Hamden councilmember Justin Farmer, when she asked that he address her as "doctor", which was requested by the Hamden Council President a few months earlier in solidarity with Jill Biden. Her resignation was requested but Horsley finished her term. Despite this political opposition, Horsley has actively supported diversity in science as a founding co-Chair of Society of Investigative Dermatology's Diversity Committee.
=== Natural fission chain-reactors on Earth === Criticality in nature is uncommon. At three ore deposits at Oklo in Gabon, sixteen sites (the so-called Oklo Fossil Reactors) have been discovered at which self-sustaining nuclear fission took place approximately 2 billion years ago. French physicist Francis Perrin discovered the Oklo Fossil Reactors in 1972, but it was postulated by Paul Kuroda in 1956. Large-scale natural uranium fission chain reactions, moderated by normal water, had occurred far in the past and would not be possible now. This ancient process was able to use normal water as a moderator only because 2 billion years before the present, natural uranium was richer in the shorter-lived fissile isotope 235U (about 3%), than natural uranium available today (which is only 0.7%, and must be enriched to 3% to be usable in light-water reactors).
Some symptoms attributable to allergic diseases are mentioned in ancient sources. Particularly, three members of the Roman Julio-Claudian dynasty (Augustus, Claudius and Britannicus) are suspected to have a family history of atopy. The concept of "allergy" was originally introduced in 1906 by the Viennese pediatrician Clemens von Pirquet, after he noticed that patients who had received injections of horse serum or smallpox vaccine usually had quicker, more severe reactions to second injections. Pirquet called this phenomenon "allergy" from the Ancient Greek words ἄλλος allos meaning "other" and ἔργον ergon meaning "work". All forms of hypersensitivity were previously classified as allergies, and all were thought to be caused by an improper activation of the immune system. Later, it became clear that several disease mechanisms were implicated, with a common link to disordered immune system activation. In 1963, a new classification scheme was designed by Philip Gell and Robin Coombs that described four types of hypersensitivity reactions, known as Type I to Type IV hypersensitivity. With this new classification, the word allergy, sometimes clarified as a true allergy, was restricted to type I hypersensitivities (also called immediate hypersensitivity), which are characterized as rapidly developing reactions involving IgE antibodies. A breakthrough in understanding the mechanisms of allergy was the discovery of the antibody class labeled immunoglobulin E (IgE).
Since this series was only discovered and studied in 1947–1948, its nuclides were never given historic names. Each of the other series have many of their nuclides given historical names. This series has an isotope of radon only produced in a rare branch (not shown in the illustration) but not in the main decay sequence. Other series produce radon in the main decay sequence, which, if occurring in mineral, would tend to migrate through the mineral and be released as radioactive gas. This series ends in thallium (or, practically speaking, bismuth) rather than lead. Its parent nuclides are essentially extinct, explaining why the series was discovered much later, after the development of artificial nucleosynthesis. Each of the other series have primordial parent nuclides. The total energy released from neptunium-237 to thallium-205, including the energy lost to neutrinos, is 49.29 MeV; from californium-249, 66.87 MeV. As the energy of the final step from bismuth to thallium, though known, will not be available until the inconceivable future, it may be better to quote the figures 46.16 MeV and 63.73 MeV to bismuth-209.
{\displaystyle \left.{\begin{aligned}{\frac {\partial I}{\partial t}}={\frac {dm}{dt}}=0&\\[4pt]f_{\text{in}}=f_{\text{out}}=f&\end{aligned}}\ \right\}\implies fE=-m{\frac {\partial I}{\partial \tau }}}
Sources: en.wikipedia.org
Santa Montefiore, author (convert) Simon Sebag Montefiore, author and Haaretz journalist;Jerusalem: The Biography was a number one non-fiction Sunday Times bestseller and a global bestseller and won The Jewish Book of the Year Award from the Jewish Book Council; descended from the banker Sir Joseph Sebag-Montefiore, the nephew and heir of the wealthy philanthropist Sir Moses Montefiore, considered by some "the most important Jew of the 19th century". Simon's mother was Phyllis April Jaffé (1927–2019) from the Lithuanian branch of the Jaffe family. The Montefiore family are descended from a line of wealthy Sephardi Jews who were diplomats and bankers all over Europe and who originated from Morocco and Italy. Eric Moonman (29 April 1929 – 22 December 2017) was Labour politician, chair of Poale Zion (Great Britain), president of Zionist Federation of Great Britain and Ireland; author of book The Violent Society; did consultancy work for ITN as expert in counter-terrorism'; appointed as member of the advisory board of the Centre for Counter Terrorism Studies at the Potomac Institute for Policy Studies. Benny Morris (Hebrew: בני מוריס; born 8 December 1948) Israeli historian of British Jewish ancestry;member of the group of Israeli historians known as the "New Historians", a term Morris coined to describe himself and historians Avi Shlaim, Ilan Pappé and Simha Flapan; Morris's work on the Arab–Israeli conflict and especially the Israeli–Palestinian conflict has won praise and criticism from both sides of the political divide. Morris regards himself as a Zionist.
=== Postnatal development === The postnatal population of dermal macrophages is achieved by the infiltration of circulating monocytes given proper CCR2 signalling, a pathway responding to chemokines. The infiltration of circulating monocytes can also be triggered through the upregulation of pro-inflammatory cytokines and chemicals such as sodium chloride. The infiltration of bone-marrow-derived monocytes generated postnatally creates a distinct population of dermal macrophages. They are LY6Chi monocytes, a type of circulating monocyte in the blood. The entry of LY6Chi monocytes to the dermis is CCR2-pathway-dependent. Their subsequent differentiation will create the postnatal population. The generation of dermal macrophages is highlighted by the expression of cell markers such as CD64, MERTK and the downregulation of CCR2.
== Patents == U.S. patent 2,163,754 was issued on June 27, 1939 – Ticket dispensing machine. U.S. patent D132,182 was issued on April 28, 1942 – Design for air conditioning unit. U.S. patent 2,336,735 was issued on December 14, 1943 – Removable cooling units for compartments. U.S. patent 2,337,164 was issued on December 21, 1943 – Means for automatically stopping and starting gas engines. U.S. patent 2,376,968 was issued on May 29, 1945 – Two-cycle gas engine. U.S. patent 2,417,253 was issued on March 11, 1947 – Two-cycle gas engine. U.S. patent 2,475,841 was issued on July 12, 1949 – Automatic refrigeration system for long-haul trucks. U.S. patent 2,475,842 was issued on July 12, 1949 – Starter generator. U.S. patent 2,475,843 was issued on July 12, 1949 – Means operated by a starter generator for cooling a gas engine. U.S. patent 2,477,377 was issued on July 26, 1949 – Means for thermostatically operating gas engines. U.S. patent 2,504,841 was issued on April 18, 1950 – Rotary compressor. U.S. patent 2,509,099 was issued on May 23, 1950 – System for controlling operation of refrigeration units. U.S. patent D159,209 was issued on July 4, 1950 – Design for air conditioning unit. U.S. patent 2,523,273 was issued on September 26, 1950 – Engine actuated ventilating system. U.S. patent 2,526,874 was issued on October 24, 1950 – Apparatus for heating or cooling atmosphere within an enclosure. U.S. patent 2,535,682 was issued on December 26, 1950 – Prefabricated refrigerator construction. U.S. patent 2,581,956 was issued on January 8, 1952 – Refrigeration control device. U.S.
=== Environmental activism === In 2004, Freeman helped form the Grenada Relief Fund to aid people affected by Hurricane Ivan on the island of Grenada. The fund has since become PLANIT NOW, an organization that seeks to provide preparedness resources for people living in areas affected by hurricanes and severe storms. In 2014, he narrated a clip titled What's Possible which had its debut at the United Nations climate summit. Freeman has donated to the Mississippi Horse Park in Starkville, Mississippi, part of Mississippi State University and Freeman has several horses that he takes there. After learning about the decline of honeybees, Freeman decided to turn his 124-acre ranch into a bee sanctuary in July 2014 beginning with 26 beehives. Freeman is a supporter of Oceana and ocean conservation.
==== Merger ==== Glaxo and Wellcome merged in 1995, to form Glaxo Wellcome plc. The merger was then considered the biggest in the UK corporate history. Glaxo Wellcome restructured its R&D operation that year, cutting 10,000 jobs worldwide, closing its R&D facility in Beckenham, Kent, and opening a Medicines Research Centre in Stevenage, Hertfordshire. Also that year, Glaxo Wellcome acquired the California-based Affymax, a leader in the field of combinatorial chemistry. By 1999, Glaxo Wellcome had become the world's third-largest pharmaceutical company by revenues (behind Novartis and Merck), with a global market share of around 4 per cent. Its products included Imigran (for the treatment of migraine), salbutamol (Ventolin) (for the treatment of asthma), Zovirax (for the treatment of coldsores), and Retrovir and Epivir (for the treatment of AIDS). In 1999, the company was the world's largest manufacturer of drugs for the treatment of asthma and HIV/AIDS. It employed 59,000 people, including 13,400 in the UK, had 76 operating companies and 50 manufacturing facilities worldwide, and seven of its products were among the world's top 50 best-selling pharmaceuticals. The company had R&D facilities in Hertfordshire, Kent, London and Verona (Italy), and manufacturing plants in Scotland and the north of England. It had R&D centres in the US and Japan, and production facilities in the US, Europe and the Far East.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.